Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders

Jerry L. Spivak, Hans Hasselbalch

Research output: Contribution to journalReview articlepeer-review

Abstract

Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplastic and non-neoplastic conditions. Hydroxycarbamide is readily absorbed and widely distributed throughout the body. It acts primarily to inhibit DNA synthesis, which underpins its use in solid tumors, viral infections and chronic myeloproliferative disorders. Hydroxycarbamide is an effective treatment for preventing transient ischemic attacks associated with thrombocytosis in chronic myeloproliferative disorders because it is a nitric oxide donor. While its mechanism of action and side-effect profile are well defined, its potential for leukemic transformation as a single agent is still a matter of controversy. Based on a search of the Medline database, this article encompasses the pharmacokinetics, pharmacodynamics, clinical use and tolerability of hydroxycarbamide, plus its potential for mutagenicity with special reference to the chronic myeloproliferative disorders. The toxicity profile of hydroxycarbamide is also discussed to enable clinicians to balance potential risks with therapeutic benefits.

Original languageEnglish (US)
Pages (from-to)403-414
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume11
Issue number3
DOIs
StatePublished - Mar 1 2011

Keywords

  • acute leukemia
  • essential thrombocythemia
  • hydroxycarbamide
  • polycythemia vera

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders'. Together they form a unique fingerprint.

Cite this